{'fraction_non_alphanumeric': 0.027210884353741496, 'fraction_numerical': 0.024489795918367346, 'mean_word_length': 4.7952755905511815, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effectiveness of doxorubicin-docetaxel or doxorubicin-cyclophosphamide combination in advanced breast cancer with distant metastasis].

Between June 1996 and March 1998 a multinational multicentric phase III randomised comparative study was made for comparing 1. the effectiveness, 2. the adverse events and 3. the quality of life of two combinations i.e. DD versus DC. 18 patients were treated with DD and 15 patients with DC. Age, tumour stage, visceral involvement, receptor status were well matched in the two groups. Good partial remission was obtained in 10 patients treated with DD whereas only seven remissions were seen in the DC arm. Response duration was similar in the 2 arms. No difference in adverse events was observed.